160 related articles for article (PubMed ID: 34599566)
1. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission.
Viazis N; Pontas C; Manolakis A; Karampekos G; Tsoukali E; Galanopoulos M; Koustenis K; Archavlis E; Christidou A; Gazouli M; Mantzaris GJ
Acta Gastroenterol Belg; 2021; 84(3):423-428. PubMed ID: 34599566
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
3. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report.
Alhalabi M; Eddin KA; Cheha K; Abbas A
Medicine (Baltimore); 2021 Sep; 100(38):e27283. PubMed ID: 34559136
[TBL] [Abstract][Full Text] [Related]
5. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
[TBL] [Abstract][Full Text] [Related]
6. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
Fumery M; Nancey S; Filippi J; Altwegg R; Hébuterne X; Boshetti G; Barraud M; Meynier J; Paul S; Roblin X
Aliment Pharmacol Ther; 2023 Jun; 57(11):1290-1298. PubMed ID: 36849714
[TBL] [Abstract][Full Text] [Related]
8. Successful use of golimumab in a patient with ulcerative colitis refractory to infliximab and adalimumab.
Cortes X; Borrás-Blasco J; Flor L; Antequera B; Fernandez-Martinez S; Molés JR; Casterá E
Int J Clin Pharmacol Ther; 2021 Mar; 59(3):257-260. PubMed ID: 33261721
[TBL] [Abstract][Full Text] [Related]
9. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
10. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
12. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
13. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
Taxonera C; Fernández-Aceñero MJ; Olivares D; Calvo M; Casis B; Bermejo F; López Serrano P; Iborra M; Mesonero F; Boscá Watts M; Díaz Del Arco C; Vera I; Olivares S; Algaba A; Alba C
Aliment Pharmacol Ther; 2022 Aug; 56(4):614-624. PubMed ID: 35509152
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
Singh S; Proudfoot JA; Dulai PS; Xu R; Feagan BG; Sandborn WJ; Jairath V
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):424-431.e7. PubMed ID: 31108227
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
17. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
[TBL] [Abstract][Full Text] [Related]
20. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis.
Kawalec P; Pilc A
Arch Med Sci; 2016 Oct; 12(5):1097-1109. PubMed ID: 27695502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
